S&P 500 Consumer Staples Sector SEC Filings — August 03, 2026

Q4 FY26 net sales of $1.95B (-2% YoY) were boosted by GOJO acquisition (+10 points), but organic sales growth is projected at only 3.5%-4.5% for FY27, signaling weak underlying demand

Adjusted EPS fell 42% YoY to $1.66, and gross margin declined 520 bps to 41.3% due to inventory step-up and higher costs, indicating severe profitability headwinds

CFO John Murphy sold 152,483 shares for ~$13.3M after exercising options at $44.48, a large insider sale that could signal peak valuation concerns or personal portfolio diversification

10% owner Hershey Trust sold 6,559 shares (~$1.15M) under a 10b5-1 plan, a pre-planned but notable reduction by the controlling shareholder, suggesting potential long-term caution

CEO and other executives were awarded phantom stock at $98.81, a retention tool that aligns management with long-term shareholder value, indicating internal confidence

Chairman & CEO and CHRO were awarded phantom stock at $50.96, signaling management's commitment to long-term performance and retention

FY27 adjusted EPS guidance of $5.70-$6.00 implies only 3%-8% growth, well below historical averages, and gross margin is expected to remain flat at ~42%, reflecting persistent cost pressures

Household segment net sales declined 18% YoY (volume -16 points) and Lifestyle segment fell 17% (volume -14 points), indicating broad-based organic weakness across core categories

Routine delisting of matured debt securities (0.125% Notes due 2026 and 3.250% Notes due 2026) is a non-event, confirming no credit distress and normal capital management

Gross margin collapsed 520 bps YoY to 41.3% in Q4 FY26, driven by GOJO acquisition costs and inflation, with no recovery expected in FY27 (flat at ~42%)

Household segment volume down 16 points and Lifestyle down 14 points YoY, signaling severe competitive pressure or demand destruction in core categories

CFO sold 100% of his exercisable options (152,483 shares) for $13.3M, a massive insider liquidation that often precedes negative news or signals overvaluation

The Hershey Trust, a 10% owner, sold shares under a 10b5-1 plan, which could be a precursor to further selling or a signal of reduced confidence in near-term prospects

Adjusted EPS of $1.66 fell 42% YoY, and the company's FY27 guidance implies only 3%-8% growth, suggesting the earnings recovery is slow and uncertain

GOJO added ~10 points to sales but caused a 520 bps gross margin decline, highlighting the risk of value-destructive M&A in a high-inflation environment

Clorox's flat gross margin guidance for FY27 (~42%) and persistent cost pressures indicate that inflation is not abating for consumer staples companies, threatening margins across the sector

FY27 organic sales growth of only 3.5%-4.5% is below the sector average and suggests the company is losing market share or facing category headwinds

The GOJO acquisition added ~28 points to Health and Wellness segment sales in Q4, and full-year FY27 sales growth of 13%-14% (including ~9.5 points from GOJO) could drive significant earnings leverage if integration costs subside

CEO and other top executives receiving phantom stock awards at $98.81 signals strong internal confidence and aligns management with shareholder value creation, a positive for long-term investors

Phantom stock awards to the CEO and CHRO at $50.96 indicate a focus on retaining key talent, which is critical for executing growth strategies in a competitive environment

If Clorox can execute on GOJO synergies and stabilize margins in FY27 (guidance flat at ~42%), the stock could see a re-rating as earnings recover from the depressed Q4 FY26 levels

The CFO's large sale was part of a pre-planned option exercise, and the stock's defensive nature could attract buyers on any weakness, especially if the sale is not followed by negative news

The Hershey Trust's 10b5-1 sale is pre-planned and may not reflect fundamental weakness; the stock's strong brand and pricing power could offer a buying opportunity if the sale creates a temporary dip

With Clorox and Coca-Cola showing mixed results, investors may rotate into pure-play defensive names like Church & Dwight and McCormick, which have stable management and less M&A integration risk

Clorox's GOJO acquisition added ~10 points to sales, but organic volumes declined sharply (Household -18%, Lifestyle -17%), highlighting a sector trend where companies rely on M&A to mask underlying demand weakness

Clorox's 520 bps gross margin decline and flat FY27 guidance show that inflation and acquisition costs are squeezing profitability, a theme likely affecting other staples companies with recent M&A

Coca-Cola and Hershey saw significant insider selling (CFO and controlling trust), while Church & Dwight and McCormick awarded phantom stock, suggesting a split in management confidence between large-cap and mid-cap staples

Philip Morris and Procter & Gamble's routine debt delistings show disciplined capital management (redeeming matured debt), contrasting with Clorox's aggressive M&A that is currently weighing on margins

Clorox's FY27 guidance (3%-8% EPS growth, flat margins) is cautious, reflecting a sector-wide trend of companies setting low expectations amid persistent inflation and uncertain consumer demand

Q4 FY26 earnings call scheduled to discuss GOJO integration, margin recovery, and FY27 guidance; watch for any changes to organic sales or margin outlook [Immediate]

Monitor for any additional insider sales following the CFO's $13.3M transaction; further selling could signal deeper concerns [Next 30 days]

Watch for any additional 10b5-1 plan filings or sales by the Hershey Trust, which could indicate a longer-term reduction in the controlling stake [Next 60 days]

Q1 FY27 results will be critical to see if organic volume declines in Household and Lifestyle segments stabilize or worsen [Next 90 days]

Monitor for any insider sales after phantom stock vests, which could signal a change in management sentiment [Next 6 months]

Watch for any changes in CEO Brendan Foley's holdings or additional phantom stock awards, which could indicate confidence in the growth strategy [Next 6 months]

Upcoming CPI and PPI reports will be key to assessing whether input cost pressures are easing, which would benefit Clorox and other staples companies [Monthly]

Monitor for any new debt issuances or refinancing activities following the delisting of matured notes, which could signal capital structure changes [Next 12 months]